Carter Sinclair News: Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat Rate this Article: 0 / 5 stars - 0 vote(s) Print Email Re-Publish

About the Author:

Carter Sinclair Org is non-profit organization that helps monitor health status, inform and educate people about health issues. Research for new approach and modern solutions to health problems. For more information please visit www.cartersinclair.org. Email at info@cartersinclair.org

Author: Carter Sinclair